Results 171 to 180 of about 1,977,520 (346)

Risk and Cost Associated With Drug–Drug Interactions Among Aging HIV Patients Receiving Combined Antiretroviral Therapy in France [PDF]

, 2019
Ludivine Demessine, Laure Peyro‐Saint‐Paul, Edward M. Gardner, Jade Ghosn, Jean‐Jacques Parienti   +4 more
openalex   +1 more source

A deep learning method for drug-target affinity prediction based on sequence interaction information mining

, 2023
Mingjian Jiang, Yunchang Shao, Yuanyuan Zhang, Wei Zhou, Shunpeng Pang   +4 more
openalex   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Pre-Clinical Drug Prioritization via Prognosis-Guided Genetic Interaction Networks

, 2010
Jianghui Xiong, Juan Liu, Simon Rayner, Ze Tian, Yinghui Li, Shanguang Chen   +5 more
openalex   +2 more sources

Drug Interactions With Excessive Daytime Sleepiness Treatments. [PDF]

J Pharm Technol
Thomas SV, Malesker MA, Hilleman DE, Dewan NA.   +3 more
europepmc   +1 more source

Drug Interactions [PDF]

Anaesthesia and Intensive Care, 1975
openaire   +2 more sources

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Severity and Management of Drug–Drug Interactions in Acute Geriatric Patients [PDF]

, 2013
Marianne Lea, Stine Eidhammer Rognan, Radojka Koristovic, Torgeir Bruun Wyller, Espen Molden   +4 more
openalex   +1 more source

Challenges to determine synergistic drug interactions in mice. [PDF]

Nat Commun
Westerman BA, Broersma Y, Wurdinger T, Noske D, Sminia P, Tannous B.   +5 more
europepmc   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source